The role of the gastrointestinal tract in the control of energy balance

被引:10
作者
Boguszewski, Cesar Luiz [1 ]
van der Lely, Aart J. [2 ]
机构
[1] Univ Fed Parana, Dept Internal Med, Endocrine Div SEMPR, BR-80060000 Curitiba, PR, Brazil
[2] Erasmus Univ, Med Ctr, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
关键词
Gastrointestinal hormones; cholecystokinin (CCK); ghrelin; incretins; oxyntomodulin (OXM); pancreatic polypeptide (PP); peptide YY (PYY); energy metabolism; obesity; metabolic syndrome (MS); human microbiome;
D O I
10.3978/j.issn.2224-4778.2014.07.01
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The gastrointestinal tract (GIT) is part of a major physiological system involved in the regulation of the body's energy homeostasis. GIT secretes several peptides that influence energy balance through regulation of food intake, energy expenditure and metabolism, besides their local effects controlling gastric-empting, gut motility and nutrient utilization. These peptides integrate a two-way communication axis with the central nervous system, particularly involving the arcuate nucleus (ARC) of the hypothalamus and the nucleus of the solitary tract (NTS). As their primary role, GIT-derived peptides act as "satiety signals" to the brain, modulating various physiological events related to the meals and the inter-meals periods. Since the pioneering studies with cholecystokinin (CCK) four decades ago, many other peptides, receptors and intracellular pathways have been revealed, mostly promoting reduction of food intake. The discovery of ghrelin in 1999 unveiled a new paradigm in this system, presenting the first and the only peripheral hormone with orexigenic properties to date. In the last years, a new player has entered into the game with the demonstration that intestinal microbiota is linked to obesity and metabolic disorders. In view of the alarming incidence of obesity, diabetes and metabolic syndrome (MS) worldwide, our understanding on how this communication axis between GIT and brain operates is critical for the development of efficient and safe therapies to fight against these major threats of human health.
引用
收藏
页码:3 / 13
页数:11
相关论文
共 62 条
[1]   The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway [J].
Abbott, CR ;
Monteiro, M ;
Small, CJ ;
Sajedi, A ;
Smith, KL ;
Parkinson, JRC ;
Ghatei, MA ;
Bloom, SR .
BRAIN RESEARCH, 2005, 1044 (01) :127-131
[2]   Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin [J].
Asakawa, A ;
Inui, A ;
Fujimiya, M ;
Sakamaki, R ;
Shinfuku, N ;
Ueta, Y ;
Meguid, MM ;
Kasuga, M .
GUT, 2005, 54 (01) :18-24
[3]   Characterization of the effects of pancreatic polypeptide in the regulation of energy balance [J].
Asakawa, A ;
Inui, A ;
Yuzuriha, H ;
Ueno, N ;
Katsuura, G ;
Fujimiya, M ;
Fujino, MA ;
Niijima, A ;
Meguid, MM ;
Kasuga, M .
GASTROENTEROLOGY, 2003, 124 (05) :1325-1336
[4]   The gut and energy balance: Visceral allies in the obesity wars [J].
Badman, MK ;
Flier, JS .
SCIENCE, 2005, 307 (5717) :1909-1914
[5]   Gut hormone PYY3-36 physiologically inhibits food intake [J].
Batterham, RL ;
Cowley, MA ;
Small, CJ ;
Herzog, H ;
Cohen, MA ;
Dakin, CL ;
Wren, AM ;
Brynes, AE ;
Low, MJ ;
Ghatei, MA ;
Cone, RD ;
Bloom, SR .
NATURE, 2002, 418 (6898) :650-654
[6]   Inhibition of food intake in obese subjects by peptide YY3-36 [J].
Batterham, RL ;
Cohen, MA ;
Ellis, SM ;
Le Roux, CW ;
Withers, DJ ;
Frost, GS ;
Ghatei, MA ;
Bloom, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :941-948
[7]   Pancreatic polypeptide reduces appetite and food intake in humans [J].
Batterham, RL ;
Le Roux, CW ;
Cohen, MA ;
Park, AJ ;
Ellis, SM ;
Patterson, M ;
Frost, GS ;
Ghatei, MA ;
Bloom, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (08) :3989-3992
[8]   PANCREATIC-POLYPEPTIDE INFUSIONS REDUCE FOOD-INTAKE IN PRADER-WILLI SYNDROME [J].
BERNTSON, GG ;
ZIPF, WB ;
ODORISIO, TM ;
HOFFMAN, JA ;
CHANCE, RE .
PEPTIDES, 1993, 14 (03) :497-503
[9]  
Boguszewski CL, 2010, ENDOKRYNOL POL, V61, P194
[10]   A Critical Analysis of the Clinical Use of Incretin-Based Therapies [J].
Butler, Peter C. ;
Elashoff, Michael ;
Elashoff, Robert ;
Gale, Edwin A. M. .
DIABETES CARE, 2013, 36 (07) :2118-2125